News

Genmab has announced positive top-line results from the phase II study of Arzerra (ofatumumab), in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), in patients with previously untreated

Nutra Pharma has completed a licensing agreement that grants XenaCare ongoing exclusive US marketing and distribution rights for Cobroxin. Cobroxin is an OTC pain reliever clinically proven to

Nymox has reported that NX-1207 has showed positive results when given to animals with hepatocellular carcinoma (HCC). NX-1207 is a novel drug in phase 3 development, for the

MedQuist, a provider of technology-enabled clinical documentation services, has bagged a preferred vendor contract from Wellmont Health System, a provider of health care services, for enterprise medical transcription

Cobra Biomanufacturing (Cobra) has signed an agreement with a European biotechnology company to provide development services for an Adenovirus-based product. The contract will focus on the application of

According to Endo Pharmaceuticals (Endo), Fortesta is a patented 2% testosterone transdermal gel for testosterone replacement therapy in male hypogonadism. It utilizes a metered dose delivery system designed

Lakewood-Amedex has announced that it is accelerating development of its broad spectrum anti-influenza product into clinical studies. Lakewood-Amedex’s (L-A) nRNA product is said to work by selectively silencing

Pfizer Japan and Astellas have reached a co-promotion agreement for a combination drug of hypertension treatment and hypercholesterolemia treatment – Caduet Combination Tablets in Japan. Pursuant to the

Angeion has posted a revenue of $6.2m for the first quarter of 2009, compared to $7.5m for the same period of 2008. The operating income for the company